Clinical Trial

The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
The use of regional anesthesia in breast surgery improves the postoperative outcome, reduces the development of infection, and weakens the perioperative immunosuppressive response associated with the response to surgical stress. The investigators hypothesize that the use of propofol / paravertebral anesthesia and analgesia will be accompanied by a decrease in serum proinflammatory cytokines and/or an increase in anti-inflammatory cytokines compared to propofol / PECS 2 anesthesia and analgesia. The research will be on 100 respondents divided into two groups. 0.5% levobupivacaine will be administered to both groups. Serum concentrations of pro- and anti-inflammatory cytokines, and lymphocyte subpopulations 1h before, 24h, and 48h after surgery will be measured. The investigators aim to compare the effect of propofol / paravertebral and propofol / PECS 2 anesthesia and analgesia on serum perioperative values of pro-inflammatory and anti-inflammatory cytokines to standardize protocols and apply the best method of perioperative analgesia in breast cancer surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-03.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-03-27
Trial Details
NCT Number NCT05816538
Lead Sponsor University of Rijeka
Conditions Paravertebral Block, Pectoralis and Serratus Plane Nerve Blocks, Breast Cancer, Immunologic Suppression, Levobupivacaine
Enrollment 100 participants
Start Date 2024-01-18
Primary Completion 2025-05 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-02